Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences reported Q2 2026 financial results with cash balance increasing to $34.0 million, extending the runway into Q2 2027 following a $35 million upfront raise in May. The net loss for the quarter was $6.9 million, or $0.57 per share, as R&D expenses increased to $4.6 million to support advancing clinical programs. Operationally, the company initiated site activation for the confirmatory Phase 3 trial of iopofosine I 131 in Waldenström macroglobulinemia, with an NDA submission planned for mid-2027. Recent ASCO data for the drug demonstrated an 87.5% overall response rate and 100% clinical benefit rate in a subset of patients.
Key figures
- Orr
- 87.5%
- Net loss
- $6.9 million
- Ga expenses
- $2.6 million
- Rd expenses
- $4.6 million
- Cash balance
- $34.0 million
- Clinical benefit rate
- 100%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.